A co-occurrence of STAG2 mutation and RAS pathways (NRAS, FLT3) mutations in 15-20% of MDS progressing to AML has also been demonstrated, indicating that the great genomic instability which characterizes the progression from MDS to AML, is associated with these mutations (205). Here, STAG2 is linked to myelodysplastic syndrome.